MA53023A - DIHYDROPYRIMIDINE DERIVATIVES AND THEIR USES IN THE TREATMENT OF HEPATITIS B VIRUS INFECTION OR HEPATITIS B VIRUS-INDUCED DISEASES - Google Patents

DIHYDROPYRIMIDINE DERIVATIVES AND THEIR USES IN THE TREATMENT OF HEPATITIS B VIRUS INFECTION OR HEPATITIS B VIRUS-INDUCED DISEASES

Info

Publication number
MA53023A
MA53023A MA053023A MA53023A MA53023A MA 53023 A MA53023 A MA 53023A MA 053023 A MA053023 A MA 053023A MA 53023 A MA53023 A MA 53023A MA 53023 A MA53023 A MA 53023A
Authority
MA
Morocco
Prior art keywords
hepatitis
virus
treatment
induced diseases
dihydropyrimidine derivatives
Prior art date
Application number
MA053023A
Other languages
French (fr)
Inventor
Zhanling Cheng
Wing Shun Cheung
Gang Deng
Yimin Jiang
Chao Liang
Qian Liu
Zhao-Kui Wan
Yanping Xu
Original Assignee
Janssen Sciences Ireland Unlimited Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Sciences Ireland Unlimited Co filed Critical Janssen Sciences Ireland Unlimited Co
Publication of MA53023A publication Critical patent/MA53023A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA053023A 2018-06-26 2019-06-25 DIHYDROPYRIMIDINE DERIVATIVES AND THEIR USES IN THE TREATMENT OF HEPATITIS B VIRUS INFECTION OR HEPATITIS B VIRUS-INDUCED DISEASES MA53023A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2018092875 2018-06-26
US201862716823P 2018-08-09 2018-08-09

Publications (1)

Publication Number Publication Date
MA53023A true MA53023A (en) 2021-05-05

Family

ID=68984711

Family Applications (1)

Application Number Title Priority Date Filing Date
MA053023A MA53023A (en) 2018-06-26 2019-06-25 DIHYDROPYRIMIDINE DERIVATIVES AND THEIR USES IN THE TREATMENT OF HEPATITIS B VIRUS INFECTION OR HEPATITIS B VIRUS-INDUCED DISEASES

Country Status (8)

Country Link
EP (1) EP3814326A4 (en)
JP (1) JP2021529188A (en)
KR (1) KR20210025596A (en)
CN (1) CN112513017A (en)
AU (1) AU2019296117A1 (en)
CA (1) CA3099605A1 (en)
MA (1) MA53023A (en)
WO (1) WO2020001448A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3645516A4 (en) 2017-06-27 2021-07-07 Janssen Pharmaceutica NV Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis b infections
US11053235B2 (en) * 2018-08-09 2021-07-06 Janssen Sciences Ireland Unlimited Company Substituted 1,4-dihydropyrimidines for the treatment of HBV infection or HBV-induced diseases
CN114989097A (en) * 2022-05-20 2022-09-02 无锡捷化医药科技有限公司 Preparation method of 5-amino-6-chloropyrimidine-4-carboxylic acid ethyl ester

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE034919T2 (en) * 2012-08-24 2018-03-28 Sunshine Lake Pharma Co Ltd 2,4,5,6-Substituted 3,6-dihydropyrimidine derivatives as hepatitis B virus (HBV) polymerase inhibitors for the treatment of e.g. chronic hepatitis
WO2017011552A1 (en) * 2015-07-13 2017-01-19 Enanta Pharmaceuticals, Inc. Hepatitis b antiviral agents
EP3645516A4 (en) * 2017-06-27 2021-07-07 Janssen Pharmaceutica NV Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis b infections

Also Published As

Publication number Publication date
CN112513017A (en) 2021-03-16
CA3099605A1 (en) 2020-01-02
EP3814326A4 (en) 2022-03-16
AU2019296117A1 (en) 2020-11-26
JP2021529188A (en) 2021-10-28
KR20210025596A (en) 2021-03-09
EP3814326A1 (en) 2021-05-05
WO2020001448A1 (en) 2020-01-02

Similar Documents

Publication Publication Date Title
MA45550A (en) DIAZEPINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF HEPATITIS B INFECTIONS
MA53023A (en) DIHYDROPYRIMIDINE DERIVATIVES AND THEIR USES IN THE TREATMENT OF HEPATITIS B VIRUS INFECTION OR HEPATITIS B VIRUS-INDUCED DISEASES
MA52586A (en) DIHYDROPYRIMIDINE DERIVATIVES AND THEIR USES IN THE TREATMENT OF HEPATITIS B VIRUS INFECTION OR HEPATITIS B VIRUS-INDUCED DISEASES
MA55020A (en) AMIDE DERIVATIVES USEFUL IN THE TREATMENT OF HEPATITIS B VIRUS INFECTION OR DISEASES INDUCED BY HEPATITIS B VIRUS
MA54560A (en) HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B VIRUS INFECTIONS
MA55286A (en) FUSIONED CYCLE PYRIMIDONE DERIVATIVES FOR USE IN THE TREATMENT OF HEPATITIS B VIRUS INFECTION OR HEPATITIS B VIRUS INDUCED DISEASES
MA54556A (en) HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B VIRUS INFECTIONS
EA201892034A1 (en) ELIMINATION OF HEPATITIS B VIRUS WITH THE HELP OF ANTI-VIRUS AGENTS
MA55796A (en) ITACONIC ACID DERIVATIVES AND THEIR USES IN THE TREATMENT OF AN INFLAMMATORY DISEASE OR A DISEASE ASSOCIATED WITH AN ADVERSE IMMUNE RESPONSE
EA200601575A1 (en) CASEIN PEPTIDES AND THEIR THERAPEUTIC APPLICATION
MA52661A (en) USE OF FUBP1 INHIBITORS IN THE TREATMENT OF HEPATITIS B VIRUS INFECTION
MX2018005230A (en) Combination therapy of an hbv capsid assembly inhibitor and an interferon.
HRP20171898T1 (en) Combination of direct acting antiviral agents and ribavirin for treating hcv patients
MA56392A (en) 2H-INDAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASES
RS63401B1 (en) 2,4-diaminoquinazoline derivatives and use thereof in the treatment of virus infections, cancer or allergies
PH12021550632A1 (en) Monomer and multimeric anti-hbv agents
RU2013148779A (en) TREATMENT OF HEPATITIS VIRUS INFECTION IN SEPARATELY OR IN COMBINATION WITH DELTA HEPATITIS VIRUS AND LIVER-LIVING DISEASES OF THE LIVER
EA201170484A1 (en) THERAPEUTIC MODE OF HEPATITIS TREATMENT, INCLUDING PEG-INTERFERON, RIBAVIRIN AND VX-950
MX2022006742A (en) Use and pharmaceutical composition of phenylisoxazolyl methylene-naphthalene-ether derivatives.
EA201890653A1 (en) COMPOSITION WITH ANTI-VIRAL EFFECT
BR112022000971A2 (en) Dihydropyrimidine derivatives and their use in the treatment of hbv infection or hbv-induced diseases
MA40805A (en) LONG-ACTION PHARMACEUTICAL COMPOSITIONS AGAINST HEPATITIS C
MA40817A (en) LONG-ACTION COMBINATION COMPOSITIONS AND METHODS FOR CONTROLLING HEPATITIS C
MA55879A (en) AMIDE DERIVATIVES USEFUL IN THE TREATMENT OF HEPATITIS B VIRUS INFECTION OR DISEASES INDUCED BY HEPATITIS B VIRUS
EP4003997A4 (en) Dihydropyrimidine derivatives and uses thereof in the treatment of hbv infection or of hbv-induced diseases